Greenhaven Bets Over $143 Million on a Turnaround at Medical Devices Leader Baxter

Core Insights - Greenhaven Associates disclosed a new position in Baxter International, acquiring approximately 6,288,349 shares for about $143.19 million, representing 2.77% of its $5.17 billion in reportable equity holdings as of September 30, 2025 [2][3][8] Company Overview - Baxter International offers a diversified portfolio of healthcare products, including dialysis therapies, infusion systems, injectable drugs, anesthesia, surgical devices, and connected care technologies, serving healthcare providers in approximately 100 countries [4][5] - The company generates revenue primarily through the sale of medical devices, pharmaceuticals, and related services [4] Financial Performance - As of November 3, 2025, Baxter's stock was priced at $18.21, down 49.1% over the past year, significantly underperforming the S&P 500 by 67.93 percentage points [3] - Baxter's revenue for the trailing twelve months (TTM) is $11.02 billion, with a net income of -$341 million, and a dividend yield of 3.78% [3] Investment Context - Baxter's stock has declined by 78.14% over the last five years, while the S&P 500 index has gained 91.37% during the same period [7] - Greenhaven's investment may indicate growing confidence in a potential turnaround under new CEO Andrew Hider, who is focusing on strengthening the balance sheet and targeting a three-times net leverage by the end of 2026 [8] - The company is also reducing dividends to save over $300 million in annual cash flow, which could improve investor sentiment if successful [8] Market Valuation - Baxter is currently trading at 9.3 times forward earnings, which is considered reasonable in the current overheated market [9]